These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 601875)

  • 1. Urinary testosterone values in patients with ovarian metastases from breast cancer.
    Secreto G
    Tumori; 1977; 63(5):457-62. PubMed ID: 601875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgens in breast cancer. III. Breast cancer recurrences years after mastectomy and increased androgenic activity.
    Grattarola R; Secreto G; Recchione C
    Am J Obstet Gynecol; 1975 Jan; 121(2):169-72. PubMed ID: 1115123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical effects associated with supranormal urinary testosterone excretion in premenopausal women with breast cancer: increased risk of postmastectomy recurrence and higher remission rate after ovariectomy.
    Secreto G; Zumoff B
    Cancer Res; 1983 Jul; 43(7):3408-11. PubMed ID: 6850646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer years after hysterectomy and bilateral ovariectomy and increased androgenic activity.
    Grattarola R; Secreto G
    Oncology; 1980; 37(1):37-40. PubMed ID: 7350554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovariectomy alone or in combination with dexamethasone in patients with advanced breast cancer and high levels of testosterone excretion.
    Grattarola R
    J Natl Cancer Inst; 1976 Jan; 56(1):11-6. PubMed ID: 943553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic oophorectomy for advanced breast cancer. The significance of metastases to the ovary and of ovarian cortical stromal hyperplasia.
    OSBORNE MP; PITTS RM
    Cancer; 1961; 14():126-30. PubMed ID: 13731389
    [No Abstract]   [Full Text] [Related]  

  • 7. Androgens in breast cancer. I. Atypical endometrial hyperplasia and breast cancer in married premenopausal women.
    Grattarola R
    Am J Obstet Gynecol; 1973 Jun; 116(3):423-8. PubMed ID: 4707544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast.
    Secreto G; Fariselli G; Bandieramonte G; Recchione C; Dati V; Di Pietro S
    Eur J Cancer Clin Oncol; 1983 Jan; 19(1):5-10. PubMed ID: 6682775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased urinary androgen excretion is a hormonal abnormality detectable before the clinical onset of breast cancer.
    Secreto G; Recchione C; Grignolio E; Cavalleri A
    Cancer Detect Prev; 1983; 6(4-5):435-8. PubMed ID: 6652637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of ovarian metastasis in therapeutic oophorectomy for advanced breast cancer.
    Lee YT; Hori JM
    Cancer; 1971 Jun; 27(6):1374-8. PubMed ID: 5088214
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary testosterone as a marker of risk of recurrence in operable breast cancer.
    Ballerini P; Oriana S; Duca P; Martinetti A; Venturelli E; Ferrari L; Dolci S; Secreto G
    Breast Cancer Res Treat; 1993; 26(1):1-6. PubMed ID: 8400317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SEVEN-YEAR SURVIVAL AFTER BILATERAL ADRENALECTOMY AND OOPHORECTOMY FOR CARCINOMATOSIS.
    TAYLOR H
    Proc R Soc Med; 1964 Aug; 57(8):676-8. PubMed ID: 14195856
    [No Abstract]   [Full Text] [Related]  

  • 13. Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.
    Gasparri ML; Casorelli A; Bardhi E; Besharat AR; Savone D; Ruscito I; Farooqi AA; Papadia A; Mueller MD; Ferretti E; Benedetti Panici P
    Tumour Biol; 2017 May; 39(5):1010428317695525. PubMed ID: 28459207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    Peters IT; van Zwet EW; Smit VT; Liefers GJ; Kuppen PJ; Hilders CG; Trimbos JB
    PLoS One; 2017; 12(1):e0168277. PubMed ID: 28125710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen excretion in breast cancer patients before and after ovarian irradiation and oophorectomy.
    DICZFALUSY E; NOTTER G; EDSMYR F; WESTMAN A
    J Clin Endocrinol Metab; 1959 Oct; 19():1230-44. PubMed ID: 13816627
    [No Abstract]   [Full Text] [Related]  

  • 16. HORMONE THERAPY OF PATIENTS WITH ADVANCED CANCER OF THE BREAST.
    SVIATUKHINA OV
    Acta Unio Int Contra Cancrum; 1964; 20():518-20. PubMed ID: 14151975
    [No Abstract]   [Full Text] [Related]  

  • 17. Anovulation and increased androgenic activity as breast cancer risk in women with fibrocystic disease of the breast.
    Gratterola R
    Cancer Res; 1978 Sep; 38(9):3051-4. PubMed ID: 679211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen excretion patterns in a patient with a metastatic hilus cell tumor of the ovary.
    Echt CR; Hadd HE
    Am J Obstet Gynecol; 1968 Apr; 100(8):1055-61. PubMed ID: 5643183
    [No Abstract]   [Full Text] [Related]  

  • 19. Androstenedione and testosterone in ovarian venous and peripheral plasma during ovariectomy for breast cancer.
    Horton R; Romanoff E; Walker J
    J Clin Endocrinol Metab; 1966 Nov; 26(11):1267-9. PubMed ID: 5924286
    [No Abstract]   [Full Text] [Related]  

  • 20. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.